Original article

Rapid non-invasive detection of Influenza-A-infection by multicapillary column coupled ion mobility spectrometry

Claus Steppert[1], Isabel Steppert[2], Thomas Bollinger[3], William Sterlacci[4]

1 Department of Pulmonology and Thoracic Oncology, Bayreuth General Hospital, Bayreuth, Germany
2 Institute for Biochemistry and Biology, Potsdam University, Germany
3 Institute for Microbiology and Laboratory Medicine, Bayreuth General Hospital, Bayreuth, Germany
4 Institute for Pathology, Bayreuth General Hospital, Bayreuth, Germany

Corresponding author:
Dr. Claus Steppert, Department of Pulmonology, Thoracic Oncology, Sleep Medicine, Klinikum Bayreuth, Preuschwitzer Str. 101, D-95445 Bayreuth, Germany
Tel.:+49 921 4004902
Fax: +49 921 400884902
E-Mail: claus.steppert@klinikum-bayreuth.de

Abstract

Infectious pathogens are a global issue. Global air travelling offers an easy and fast opportunity not only for people but also for infectious diseases to spread around the world within a few days. Therefore a rapid on-site screening of infected people is urgently needed.

Due to the small size and easy handling, the ion mobility spectrometry coupled with a multicapillary column (MCC-IMS) is a very promising, sensitive method for the on-site identification of infectious pathogens based on scents, volatile organic compounds (VOCs).

The purpose of this study was to prospectively assess whether differentiation between patients suffering from common cold and those from Influenza-A-infection based on VOCs with MCC-IMS is possible. Nasal breath was investigated in 24 consecutive patients suspected of having Influenza-A-infection by MCC-IMS. In 14 Influenza-A-infected patients, infection was proven by PCR of nasopharyngeal swabs. Ten patients with negative PCR diagnosis served as controls. For picking up relevant VOCs in MCC-IMS spectra, software based on cluster analysis followed by multivariate statistical analysis was applied. With only four VOCs canonical discriminant analysis was able to distinguish Influenza-A-infected patients from PCR- negative patients with 100% sensitivity and 100% specificity.

This present proof-of-concept- study yields encouraging results showing a rapid diagnosis of viral infections in nasal breath within 5 minutes by MCC-IMS. The next step is to validate the results with a greater number of patients with Influenza-A-infection as well as other viral diseases.
Registration number at ClinicalTrials.gov NCT04282135.

Introduction

Air travel not only leads to global connection of people and goods but also to an easy spread of infectious diseases [1]. During the SARS epidemic non-contact temperature measurements were used to recognize infected passengers before boarding but even for the detection of fever there is a lack of specificity and sensitivity [2]. A Chinese colleague who became symptomatic on her flight back to China infected the first German COVID-19 patient. So a rapid detection of communicable viral diseases is urgently needed not only to avoid spread by air travel but also to detect and cut infection chains.

Ancient Greek physicians already used their sense of smell to detect diseases, especially infectious diseases [3]. These scents are volatile organic compounds (VOC) released during the metabolism of the bacteria or the host. Different analytic procedures including multicapillary column coupled ion mobility spectrometry (MCC-IMS) can be used to differentiate between bacterial species in vitro [4,5]. A detection of bacterial infection could also be achieved in the breath of infected animals as well as in tuberculosis-infected humans [6,7]. Unlike bacteria, viruses do not have a metabolism of their own but VOCs can also be detected when produced by the infected host cells [8].

The present study was designed as a proof-of-concept to show whether it is possible to detect Influenza-A-infections by MCC-IMS of exhaled breath.

Methods

Patients

Eligible patients included male of female adults (aged ≥ 18 years) that were admitted to our hospital with suspected Influenza-A-infection. According to hospital policies in every patient a nasopharyngeal swab was taken for the PCR- analysis of virus RNA. Patients were consecutively asked to participate in the study.

The study was approved by the ethics committee of the university of Erlangen (Nr 426_18 B) and conducted according to the principles of the Declaration of Helsinki, good clinical practice and the European General data protection regulation. All patients gave written informed consent prior to participation. The study is registered at ClinicalTrials.gov (NCT04282135).

PCR analysis

Influenza-A was tested by taking a deep nasopharyngeal swab applying the "Xpert®Nasopharyngeal Sample Collection Kit for Viruses" (Cepheid, Maurens-Scopont, France) and performing Influenza-A PCR with the "Xpert® Xpress Flu/RSV" (Cepheid) on the "Infinity" (Cepheid).

Breath sampling and IMS analysis

As the primary replication site of the Influenza-A virus is the nasopharyngeal mucosa, nasal breath was aspirated for 10 seconds during normal respiration by foam cuffed oxygen catheter (#01442958, Asid-Bonz, Herrenberg, Germany) connected via a 0.22µm Filter (Navigator Lab Instruments, Tinajin, China) and a Perfusor Line (B Braun, Melsungen, Germany) to the MCC-IMS and directly analyzed without any pre-analytic procedures. Every patient was examined by this procedure in the first 24h after admission to ensure enough virus loads in the upper airways.

For the VOC analysis a MCC-IMS-device from STEP Sensortechnik und Elektronik, Pockau, Germany (STEP IMS NOO) was used. The breath sample was drawn into the sampling loop using an internal pump with a flow rate of 200 milliliter per minute. In the sampling loop the collected sample was pre-separated by isothermally heated multicapillary gas chromatography column (60°C) into single analytes, which finally entered the IMS unit based on their retention times. In the IMS unit the analytes were ionized by beta radiation with a tritium source (99 MBq). Afterwards the generated ions were accelerated in a 50-mm-long driftube under the influence of an electric field (400 V/cm) towards the detector which is also tempered to 60°C. On their drift way they collide with air molecules from the drift gas (400 ml/min) flowing in the opposite direction getting separated depending on their ion mobilities and detected by the collector electrode sampled every 10µs. IMS measurements were performed in positive ionization mode. The received IMS spectra were stored internally in the device and later analyzed offline.

The used IMS device is equipped with a circulation filter and internal gas circulation. Using a circulation pump, ambient air filtered by activated carbon was provided as drift gas and analysis gas (20 ml /min) to the device.

For the IMS- settings see web-only Supplementary Table S1.

IMS data analysis

For a total of 240s one spectrum was derived every second of retention time and a drift time of 20.48ms. As the VOC are physically determined by their retention time and the drift time heatmaps were generated with retention time on the Y-axis and drift time on the X-axis.

These heatmaps were further analyzed by proprietary cluster analysis software using support vector machine [9]. After baseline correction for noise the software determines the clusters based on the signal threshold and categorizes them by retention time and drift time. Depending on these parameters the clusters are numbered.

see web-only Supplementary Table S2

Statistical analysis.

For the demographics and laboratory findings descriptive statistics were used. Due to the high cross-correlation of the clusters multivariate analysis had to be employed. We decided to perform a stepwise canonical discriminant analysis for the classifier.

The discriminant analysis was aimed for a maximal reduction of Wilks-Lambda with maximum significance of F to enter a variable of 0.05 and a minimum significance to remove of 0.1. Cross-validation was performed by the leave-one-out method.

For the statistical analysis we used IBM SPSS 26.0 (IBM, Armonk, NY).

Results

Patient characteristics

Between February 15th 2020 and March 5th 2020 24 patients with suspected Influenza-A-infection and PCR confirmed Influenza-A status were included in our study. For details please refer to table 1.

Demographics	Influenza-A negative	Influenza-A positive	Total
Male/Female	7/3	4/10	11/13
Age (yrs)	61.6 ± 14.8	69.9 ± 13.2	66.4 ± 14.2
Leukocytes [G/L]	7.3 ± 3.7 1.5-11.5	7.8 ± 2.7 2.2 – 12.1	7.6 ± 2.9 1.5 -12.1
CRP [mg/L]	38.5 ± 28 4-66	76 ± 64 1 -240	65 ± 57 1 -240
PCT [ng/L]	2.2 ± 1.8 1-5.6	3.7 ± 9.1 0.7-35.4	3.3 ± 7.6 0.7 – 35.4

Table1:

Demographics of included patients including leukocyte count C-reactive Protein (CRP) and procalcitonine (PCT) as inflammation markers

MCC-IMS

Using cluster analysis software a total of 1033 clusters were found. Clusters where the median signal intensity of Influenza-A negatives exceeded the median signal intensity of Influenza-A positives were omitted, resulting in 74 usable clusters.

Using stepwise canonical discrimination analysis 7 clusters could optimally minimize Wilks Lambda to 0.062. Despite an imbalance of gender between infected and non-infected subjects gender had no influence on discrimination in the multivariate analysis. Using these 7 clusters a sensitivity of 100% and a specificity of 100% could be found at cross-validation by leave-one-out. (See web-only Supplementary Table S3 and S4).

Additionally another 3 clusters could be removed maintaining 100% specificity and 100% sensitivity at cross validation of the remaining 4 clusters. (see web-only Supplementary Table S5 and box plots Fig. S2).

Using only 3 clusters there was only 1 false positive and 1 false negative (Tab. 2) leading to a sensitivity of 92.9% and a specificity of 90%.

Classification Results[a,c]					
		Group	Predicted Group Membership		Total
			neg	pos	
Original	Count	neg	10	0	10
		pos	0	14	14
	%	neg	100	0	100
		pos	0	100	100
Cross-validated[b]	Count	neg	9	1	10
		pos	1	13	14
	%	neg	90	10	100
		pos	7.1	92.9	100

a. 100,0% of original grouped cases correctly classified.

b. Cross validation is done only for those cases in the analysis. In cross validation, each case is classified by the functions derived from all cases other than that case.

c. 91,7% of cross-validated grouped cases correctly classified.

Table 2
Results of linear canonical discrimination analysis using clusters c_521 (164s, 4.41ms), c_378 (119s, 4,56ms) and c_116 (44s, 2,69ms). Neg = Influenza-A negative, pos = Influenza-A positive.

Fig. 1 shows the separation of the positive and negative patients in a 3D-plot of the signal intensities of these cluster c_116, c_378 and c_521.



Fig. 1. 3D- scatterplot of signal intensities for cluster c_116, c_378 and c_521. White balls = Influenza-A negative, black balls = Influenza-A positive.

Discussion

To the best of our knowledge this is the first study indicating that Influenza-A-infections can be detected by aspirating nasal breath in infected patients.

There is only little known about breath analysis in viral diseases.
Most of the studies either have analyzed headspace over cell cultures [10,11] or the influence of vaccination on breath VOCs [12]. In another study dogs were used to detect the smell of virus infected cell cultures [13].

There are studies using “breath biopsy” for the detection of cancer by differential ion mobility spectrometry but the device used in this study needs pre-analytic procedures with absorption/desorption tubes while using the STEP device the breath is aspirated during normal breathing and analyzed instantaneously [14]. This can also be performed by less trained personal and is well tolerated by the patients.

Another advantage is the speed of the analysis. Though using a retention time of 240 seconds most relevant VOCs could be found in the first 180 seconds. So a reduction of the analysis time to 3 minutes seems to be possible.

Compared to PCR as the gold- standard, MCC-IMS is not only faster but does not need reagents and other supplies where shortages of swabs especially flocked nasopharyngeal swabs and of less sensitive swabs have emerged in the SARS-CoV-2 pandemics.

Compared to gas chromatography coupled mass spectrometry the device is quite small, easily portable and can be used as a point-of-care diagnostic.

PCR-analysis of nasopharyngeal swabs used for the detection of viral disease may be false negative if the replication site is in the distal airways or the lung parenchyma [15]. Using a deep exhalation procedure all respiratory compartments are accessible by breath analysis.

One shortcoming of our study is the sample size. Due to the late start of the study and the weak Influenza season 2020 only few patients could be analyzed and no validation cohort was available.

After demonstrating the proof-of-principle for the MCC-IMS diagnostic in respiratory infections in the current study, future studies shall address the optimization of sampling procedure and analysis algorithms as well as extension to other viral infections. Besides statistical methods we are planning to implement methods of artificial intelligence.

Conclusion

To cut infection chains effective screening for Influenza-A and other communicable virus diseases is urgently needed.

In this proof-of-concept study MCC-IMS was able to discriminate Influenza-A-infections by simple aspiration of nasal breath during normal breathing. As the whole analysis takes less than 5 minutes MCC-IMS allows for rapid screening.

Further investigation of this method is needed as well as application to other viral diseases.

Conflict of interests:

The authors state that there is no conflict of interests

Funding:

No external funding

Authors Contribution

CS Conceptualization, Data curation, Formal Analysis, Methodology, Investigation, Writing – original draft, Writing – review & editing

IS Visualization, Formal Analysis, Writing – original draft, Writing – review & editing

TB Investigation, Writing – review & editing

WS Writing – review & editing

Prior Presentation:

The paper has been submitted to medrxiv.org

References

1. Pavia AT. Germs on a Plane: Aircraft, International Travel, and the Global Spread of Disease. Journal of Infectious Diseases 2007 195:621-22

2. Ng DK, Chan CH, Lee RS, Leung LC. Non-contact infrared thermometry temperature measurement for screening fever in children. Ann Trop Paediatr 2005 25:267-75

3. Shirasu, M, Touhara, K. The scent of disease: volatile organic compounds of the human body related to disease and disorder. J Biochem 2011, 150 (3), 257−266

4. Jünger M, Vautz W, Kuhns M, Hofmann L, Ulbricht S, Baumbach JI, Quintel M, Perl T. Ion mobility spectrometry for microbial volatile organic compounds: a new identification tool for human pathogenic bacteria. Appl Microbiol Biotechnol 2012 93:2603-14

5. Steppert C, Dick T, Steppert I, Bollinger T, Becher G. Rapid in vitro detection of resistant strains by MCC-IMS. European Respiratory Journal 2018 52: PA2655

6. Purkhart R, Köhler H, Liebler-Tenorio E, Meyer M, Becher G, Kikowatz A, Reinhold P. Chronic intestinal Mycobacteria infection: discrimination via VOC analysis in exhaled breath and headspace of feces using differential ion mobility spectrometry. J Breath Res 2011 5:027103

7. Sahota AS, Gowda R, Arasaradnam RP, Daulton E, Savage RS, Skinner JR, Adams E, Ward SA, Covington JA. A simple breath test for tuberculosis using ion mobility: A pilot study. Tuberculosis 2016 99:143-6

8. Traxler S, Bischoff AC, Saß R, Trefz P, Gierschner P, Brock B, Schwaiger T, Karte C, Blohm U, Schröder C, Miekisch W, Schubert JK. VOC breath profile in spontaneously breathing awake swine during Influenza-A-infection. Sci Rep 2018 8:14857

9. Purkhard R Klassifikation von Ausatemluft anhand ihrer differenziellen Ionenbeweglichkeitsspektrogramme. Humboldt-Universität Berlin, Institut für Informatik, diploma thesis 2010

10. Schivo, M, Aksenov, AA, Linderholm, AL, McCartney, MM, Simmons, J, Harper, RW, Davis, CE. Volatile emanations from in vitro airway cells infected with human rhinovirus. J Breath Res 2014, 8, 037110

11. Aksenov AA, Sandrock CF, Zhao W, Sankaran S, Schivo M, Harper R, Cardona CJ, Xing Z, Davis CE. Cellular Scent of Influenza Virus Infection. Chembiochem 2014 15:1040–1048

12. Phillips, M, Cataneo, RN, Chaturvedi, A, Danaher, PJ, Devadiga, A, Legendre, DA, Nail, KL, Schmitt, P, Wai, J. Effect of influenza vaccination on oxidative stress products in breath. J Breath Res 2010, 4, 026001

13. Angle TG, Passler T , Waggoner PL , Fischer TD , Rogers B , Galik PK, Maxwell HS. Real-Time Detection of a Virus Using Detection Dogs. Front Vet Sci. 2016 2:79.

14. van der Schee M, Pinheiro H, Gaude E. Breath biopsy for early detection and precision medicine in cancer. Ecancermedicalscience. 2018 12:ed84.

15. Winichakoon P, Chaiwarith R, Liwsrisakun C, Salee P, Goonna A, Limsukon A, Kaewpoowat B. Negative Nasopharyngeal and Oropharyngeal Swabs Do Not Rule Out COVID-19. J Clin Microbiol 58:e00297-20